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Abstract
I believe that the FDA guidelines have already had an impact in encouraging good practice in the
use of PROs. There are, however, important improvements that need to be made to the guidelines,
particularly in the use of health status and quality of life terminology. It is essential to distinguish
between health status and quality of life and to use both terms. Nothing is to be gained and a great
deal will be lost if the term quality of life (which has been misused as an umbrella term in the past)
is abandoned and replaced with the term health status. Patients want us to consider their quality
of life as well as their health. To abandon the term would be to forget about their quality of life and
focus only on their health. Patients are well able to tell us what quality of life means to them and
to rate the impact of a condition on their quality of life if we use individualised quality of life
measures and individualised condition-specific quality of life measures to allow them to do so.
Although my experience with PRO measures would support many of the recommendations in the
guidelines there are others that I would not fully agree with or would contradict on the basis of my
own research evidence. I have provided references to that research and hope that the FDA will
feel able to do the same when they finalise their guidelines.
Introduction
The US Department of Health and Human Services Food
and Drug Administration (FDA) made public in February
2006 a document entitled 'Guidance for Industry Patient-
Reported Outcome Measures: Use in Medical Product
Development to Support Labeling Claims DRAFT GUID-
ANCE'. I have a particular interest in this draft guidance as
I specialise in the design, development and use of PRO
measures and license them for use in clinical trials, other
research and routine clinical practice. My measures
include:
• the Diabetes Treatment Satisfaction Questionnaire
(DTSQ) in its status (DTSQs) and change (DTSQc) forms
[1-6] and related measures for other conditions including
the HIVTSQ, RTSQ, RetTSQ, GHerpTSQ, ThyTSQ [7-12],
and the newly designed DTSQ-Teen and DTSQ-Parent.
The DTSQs and DTSQc are fully linguistically validated in
65 language versions
• the Well-being Questionnaire (e.g. W-BQ12) [3,13-18]
generic measure of well-being is psychometrically vali-
dated for a range of populations including those who
have diabetes (type 1 and type 2) macular disease and
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dated in 37 language versions
• the ADDQoL measure of the impact of diabetes on qual-
ity of life [4,19] with related measures for other condi-
tions including RDQoL, RetDQoL, MacDQoL, HDQoL,
A-RHDQoL, ThyDQoL, ADDQoL Teen [12,20-27] and
recently designed ADDQoL Jnr (for 5–8 year olds) and
ADDQoL Jnr+ (for 9–12 year olds). The ADDQoL,
MacDQoL and RetDQoL are linguistically validated in
16–25 language versions.
I welcome the FDA guidance as a much needed source of
information about the standards required in PRO design,
linguistic validation and psychometric validation. I recog-
nise that the guidance may be very useful in encouraging
good practice.
I was one of the 56 individuals/organisations who sub-
mitted comments on the draft FDA guidelines by their
deadline of 4th April. My original comments can be
viewed with others on the FDA website [28]. I also
attended a meeting in Washington DC on 29th June 2006
organised by ISOQOL (the International Society for Qual-
ity of Life Research) where the FDA was represented. I had
expected this meeting to facilitate discussion of the draft
guidelines with the FDA.
Unfortunately the FDA representatives stayed only long
enough to give their own opening presentations and
respond to specific questions arising from those presenta-
tions but left before the following talks by ISOQOL mem-
bers with lifetimes of experience of working with PROs
providing feedback on the draft guidelines and sugges-
tions for improvements. The FDA missed out on a valua-
ble opportunity to learn from experts in the field. There is
to be a follow up meeting before the ISOQOL conference
in Lisbon in October and it is to be hoped that the FDA
will come to listen as well as to speak. It was heartening to
find that the FDA did appear to have taken note of some
of the feedback previously provided and they encouraged
submission of further written comments even though the
original deadline is passed. Here I select some of the key
issues raised in the comments I submitted to the FDA and
provide some input following the Washington meeting.
Discussion
References
First it should be noted that the FDA provided no refer-
ences in their guidelines. It is unclear why they feel it is
unnecessary to back up their statements with evidence
and examples. Their guidelines will be a great deal more
credible and helpful in improving standards applied in
developing and using PROS when properly referenced.
Terminology, in particular 'health status' and 'quality of 
life'
I welcome the use of the term 'patient-reported outcome
(PRO) measures' in place of the ubiquitous and, usually
inaccurate, use of 'quality of life measures'. Previously 'qual-
ity of life' was used as an umbrella term to cover a wide
range of PRO measures including health status instru-
ments which are actually measuring quality of health and
not quality of life. This distinction is important and failure
to recognise the difference has led to some highly mislead-
ing conclusions and misguided policies. I emphasised the
importance of distinguishing between quality of life and
health status in a commentary in the Lancet in 2001 [29]
where I gave the example of the influential UK Prospective
Diabetes Study (UKPDS) as one which used health status
measures but in the published report the authors inter-
preted their findings as if they were measuring quality of
life [30]. The UKPDS authors concluded that intensified
treatment for Type 2 diabetes had no impact on quality of
life and recommended widespread use of intensified treat-
ment. In fact their findings showed there was no impact of
intensified treatment on patients' perceptions of the qual-
ity of their health and their quality of life was not meas-
ured. This is a very different conclusion and a far less
desirable one than the one reached erroneously by the
UKPDS authors.
Line 31 of the draft guidance defines a PRO as 'a measure-
ment of any aspect of a patient's health status that comes
directly from the patient...'. It seems that the FDA was here
misusing the term 'health status', in the way that previously
the term quality of life was misused, as an umbrella term
to encompass a variety of other outcomes, which lines 35
and 36 suggest include symptoms, activities of daily living
and quality of life. Thus quality of life measures are here
conceptualised as a subset of health status measures
instead of health status being (wrongly) seen as one of a
range of quality of life measures and still there is no recog-
nition of the importance of distinguishing between these
two key concepts, health status and quality of life.
If the term 'health status' is upgraded in this way to take
over from 'quality of life' as an umbrella term we will have
as much, if not more, confusion over terminology and,
worse still, patient reported outcomes will come to be
seen as measures of health as viewed by the patient. There
is a danger that clinical trials will be satisfied with meas-
uring patients' reports of symptoms and will fight shy of
measuring what the FDA are describing as 'extremely com-
plex concepts such as quality of life'. The great advantage of
the term 'PRO' is that it is a neutral term that covers all
patient reported outcomes including their satisfaction
with their treatment, their well-being, their quality of life
and their symptoms and health without needing an
interim term such as 'health status' to limit the definition.Page 2 of 8
(page number not for citation purposes)
Health and Quality of Life Outcomes 2006, 4:78 http://www.hqlo.com/content/4/1/78If the FDA really feels the need to describe the kind of out-
comes that PROs refer to then they might consider 'health
and quality of life outcomes' which is the phrase eventually
agreed upon as the title of the present journal. This phrase
makes it clear that health outcomes are one form of PRO
and quality of life outcomes are another and both are
important but different, an issue discussed in the first edi-
torial of the journal written by myself and the editor, Mar-
cello Tamburini [31].
However, in many ways it is more comprehensive and
simpler to refer just to 'Patient Reported Outcomes' and
make it clear that PRO measures can include measures of
symptoms, health status, treatment satisfaction, well-
being and quality of life. At the Washington meeting, the
three representatives from the FDA, Sahar M Dawisha,
Edwin P Rock and John Powers, gave three interrelated
presentations on the thinking behind the guidelines in
preparation. It was encouraging to see that they were no
longer defining a PRO as 'a measurement of any aspect of a
patient's health status': perhaps they were making good use
of our written comments. Instead, PRO was defined as an
'element of feeling or function affected by disease, reported
directly by patients'. While welcoming this broader defini-
tion that does not focus entirely on health status it is still
unnecessarily limited in focusing on 'feeling or function'
(what about cognitions and knowledge/understanding of
the treatment and condition, adherence and self-care
behaviours?) and only those that are affected by disease
(what about the effects of treatment?). I suggest that PROs
are well-enough defined by their name – outcomes
reported by patients – if the FDA feels the need to narrow
down the kind of PRO measures that they accept they can
do so without interfering with the definition of a PRO.
Conceptualising quality of life
The guidance described the concept of quality of life as
'extremely complex'. The FDA offered the following unhelp-
ful definition of Quality of Life in the glossary: 'A general
concept that implies an evaluation of the impact of all aspects
of life on general well-being. Because this term implies the eval-
uation of nonhealth-related aspects of life, it is too broad to be
considered appropriate for a medical product claim'. Surely it
should be the ultimate aim of a treatment to benefit
patients' quality of life? We may sometimes have to settle
for reducing the damage done to quality of life by a med-
ical condition such as diabetes but we will still need a def-
inition of quality of life. If we try to define what quality of
life is in a way that is appropriate for everyone it is indeed
a very complex and perhaps an impossible task. However,
if we follow the advice of Dick Joyce and define quality of
life in terms of what the individual thinks it is [32] and
measure it using individualised measures (e.g. [19,33]), it
becomes a manageable, measurable and useful concept. It
is very important for patients that clinical trialists do not
duck the issue of measuring the impact of new treatments
on the quality of life of individual participants in trials
and measure only the quality of their health. It is the big-
ger issue of quality of life that is most important to
patients and it makes a great deal of difference to them if
new treatments impair their quality of life or improve
their quality of life. Only the patients can tell us how a
treatment affects their quality of life using individualised
PRO measures designed for the purpose (e.g.[19-22,25]).
My ADDQoL questionnaire provides an overview ques-
tion about quality of life per se as well as measuring the
impact of diabetes on quality of life. There have been sev-
eral studies which have shown significant benefits to qual-
ity of life on the overview present quality of life item as
well as reductions in the negative impact of diabetes on
quality of life (e.g. [34,35]). The definition of quality of
life that I used as a basis for the design of the ADDQoL
and related measures is that recommended by Joyce: qual-
ity of life is what the individual thinks it is. The individ-
ual's view of their quality of life may indeed include
aspects of life that are not health related although as med-
ical conditions become more severe and/or their treat-
ment becomes more demanding and/or invasive, the
aspects of life that are not health related diminish.
I believe it is essential that we face up to the importance of
defining and measuring quality of life per se and do not
avoid the issue or confuse matters further, as the FDA did,
by defining quality of life in terms of well-being but then
not defining well-being in their glossary! There are many
measures of well-being which typically include subscales
to measure depression and anxiety, energy, and, some-
times, positive well-being (e.g.[13,36]). When a person is
depressed and anxious their quality of life is also likely to
be impaired. However, someone who is not depressed or
anxious may nevertheless feel that their quality of life
would be much improved if they didn't have diabetes.
Thus measures of well-being are no substitute for meas-
ures of quality of life. I recommend that the FDA adopt a
simple patient-centred definition for the concept of qual-
ity of life – quality of life is what the individual concerned
thinks it is [32] and encourages the considerable efforts
made to date to measure individualised quality of life (e.g.
the SEIQoL [33] which is the focus of a special interest
group in ISOQOL) and the impact of medical conditions
on individual's quality of life (e.g. the ADDQoL [19]
which has already been welcomed by several reviewers
despite the first publication of the ADDQoL being only six
years old [37-39]).
Health-related quality of life (HRQL)
HRQL was defined in the draft guidelines as 'A multido-
main concept that represents the patient's overall perception of
the impact of an illness and its treatment. An HRQL measurePage 3 of 8
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emotional and cognitive), and social functioning. Claiming a
statistical and meaningful improvement in HRQL implies: (1)
that the instrument measures all HRQL domains that are
important to interpreting change in how the study population
feels or functions as a result of treatment; and (2) that improve-
ment was demonstrated in all of the important domains.'. This
definition would seem to allow for some health status
measures to be classed as HRQL measures (e.g. SF-36) for
some patient groups as well as condition-specific quality
of life measures (e.g. ADDQoL [4,19]). This is because the
FDA refers to the patients' perception of the impact of an
illness and its treatment but does not make explicit
whether that impact is on their health or on their QoL. I
think this encourages health status measures to be misla-
belled as if they were quality of life measures (or health-
related quality of life measures) when they are more accu-
rately construed as measures of the quality of health and
creates problems of interpretation discussed above and
elsewhere [29].
Point (1) above will exclude many generic tools which do
not adequately assess the impact of specific conditions on
aspects of life important for quality of life: this may be an
important step forward. For example, the aspect of life
measured by the ADDQoL that is most impaired by dia-
betes is freedom to eat as I wish, is not measured by any
other quality of life measure that I know of. Awareness of
this major influence of dietary restrictions on quality of
life led to the evaluation of the DAFNE (Dose Adjustment
For Normal Eating) approach to insulin treatment for dia-
betes with major benefits to quality of life, treatment sat-
isfaction, well-being and glycaemic control [35]. The
DAFNE approach was supported by the recent National
Service Framework for Diabetes in the UK and the Depart-
ment of Health funded roll out of the approach nation-
wide. The value of DAFNE would not have been
demonstrated by generic health status tools such as the
EQ5D or the SF-36 which are all too often mislabelled
HRQoL measures.
Point (2) above: I would take issue with the suggestion
that improvement needs to be demonstrated in all of the
important domains in a HRQL instrument. First because
improvement can only be demonstrated in domains
where deficits are apparent to start with, however impor-
tant the domain may be, and we cannot expect that defi-
cits will always be found for all important domains in all
uses of a questionnaire. Secondly it seems unreasonable
to expect to see benefits for all important domains even if
there were deficits to start with. The outstandingly success-
ful DAFNE approach did not achieve significant improve-
ments for all the domains of the ADDQoL even though it
showed significant benefits on the overall score and on
many specific domains [35]. Just as we wouldn't reject a
diabetes treatment because lipids did not improve along-
side improvements in blood glucose control so too we
should not reject a treatment because not all domains of
a PRO measure improve.
Quality of life in the taxonomy of PROs
Quality of life does not appear in Table 1 of the draft
guidelines. The use of the term 'Overall health status' rather
confirms my concern that the FDA was substituting global
misuse of the term 'quality of life' with global misuse of the
term 'health status'. Health status measures can be useful
but they are not everything. Quality of life and health-
related quality of life measures are an essential subset of
PRO measures for which health status measures provide
no substitute. It is to be hoped that the FDA will continue
to revise their definitions and taxonomy and, like ISO-
QOL, will recognise the value of individualised quality of
life measures.
Modification of PRO instruments
I welcome efforts to discourage users of established vali-
dated instruments from tinkering with the wording of
questionnaires unnecessarily while referring to the valida-
tion of the original instruments as evidence for the modi-
fied instrument's validity and reliability (lines 176–181).
However, with some instruments, such as the DTSQc, it is
necessary to modify the instructions to relate specifically
to the conditions of the clinical trial in which it is being
used and we now have considerable evidence to show that
the psychometric properties of the DTSQc remain robust
to such changes [5,6]. I encourage users of the DTSQc to
check the psychometric properties on each new use but
would not go as far as to say that each new use (with mod-
ified instructions) should be treated as if it is a new meas-
ure.
Comparison of present state with an earlier state
In lines 339 to 343 the FDA warned against instruments
that rely on patients' memory in recalling experiences over
a period of time: 'It is usually better to construct items that ask
patients to describe their current state than to ask them to com-
pare their current state with an earlier period..'. While this
may sometimes be good advice there are exceptions.
Where measurement of patient satisfaction with treat-
ment is concerned we often find that patients report being
very satisfied with their current treatment until they expe-
rience a better treatment and then they want to be able to
say that they are much more satisfied with the new treat-
ment. If they have been given a status measure of treat-
ment satisfaction at baseline and have given optimum
responses showing they are very satisfied, they will not be
able to respond any more positively at follow up when
they are using a new treatment with which they are much
more satisfied. It was to overcome such ceiling effects with
the DTSQs status measure of satisfaction with diabetesPage 4 of 8
(page number not for citation purposes)
Health and Quality of Life Outcomes 2006, 4:78 http://www.hqlo.com/content/4/1/78treatment that I designed and developed the DTSQc meas-
ure of change in treatment satisfaction for use at follow
up. This allows patients to say that they were very satisfied
at baseline with the treatment they were using prior to the
trial but are very much more satisfied with the new treat-
ment they experienced within the trial. The DTSQc is also
useful in crossover trials [6]. We are finding that the
DTSQc provides valuable data when used in addition to
the DTSQs and overcomes ceiling effects that are some-
times found when the DTSQs is used alone [5,6].
Asymmetric response options
Lines 367–369. It is suggested quite appropriately that
response options should not bias the direction of
responses. However, the example given suggests that
offering one negative choice, one neutral choice and two
or more positive choices on a scale will make it more
likely that patients will respond that they feel or function
better. We have actually changed the symmetric response
options originally used in the MacDQoL to asymmetric
response options because respondents rarely used the
response options which indicated that their quality of life
would be worse if they didn't have macular disease as few
people see any benefits of having this degenerative eye
condition [22,23]. It is true that patients are more likely to
respond in the direction that has more response options
but this was the reason for making the scale asymmetric
and not the result of asymmetry.
Weighting
Lines 416 to 419. 'Equally weighted scores for each item are
appropriate only when the responses to the items are relatively
uncorrelated. Otherwise the assignment of equal weights will
overweight correlated items and underweight independent
items.' William Lenderking and colleagues in their Wash-
ington presentation asked 'Does this statement imply that
uncorrelated items should be grouped together (hence under-
mining internal consistency), or simply that redundant
domains should not be included?' and recommended that the
FDA's draft passage on weighting be deleted. I agree. If the
FDA wish to evaluate the role of weightings further then
they might consider individualised condition-specific
quality of life measures where the rating of impact of the
condition on each life domain is weighted by the individ-
ual's rating of the importance of the domain to the indi-
vidual's quality of life. Such weightings have been shown
to alter substantially the rankings of weighted impact
scores across domains compared to unweighted impact
scores [19,40]. Weightings here play a key role in convey-
ing the individual's view of the impact of their condition
on their quality of life.
Minimum important difference (MID)
Table 4. I agree that it can be helpful to consider the MID
for clinical measures which are intermediate outcomes
that may not be important outcomes for the patient in
themselves but only in so far as they are predictors of
other outcomes that are important (e.g. HbA1c measures
of blood glucose in diabetes). With some PRO measures
that ask about symptoms, health status or visual function-
ing without asking about the importance of the issue in
question for the patient, it may also be useful to deter-
mine MID. However, a statistically significant difference
on measures of treatment satisfaction that have been
designed explicitly to measure issues of importance to
patients (e.g. DTSQ) will necessarily be an important dif-
ference. So too will be a statistically significant difference
on an individualised measure of the impact of a condition
on quality of life, where the importance of an aspect of life
for an individual's quality of life is part of the assessment
(e.g. ADDQoL).
I was not impressed with the list of ways in which people
have attempted to derive MIDs that the FDA has reviewed
and the comments made by the FDA suggested that they
have serious reservations too (lines 554–564). I also have
major concerns about the first method outlined (551–
554) which was not commented on by the FDA. This
method involved mapping changes in PRO scores to clin-
ically relevant and important changes in non-PRO meas-
ures and suggests that PRO measures be judged by their
similarity to non-PRO measures such as spirometry scores
in asthma. While it may be appropriate to expect some
PRO measures such as those measuring health status or
visual function to map onto clinical measurements, it is
not appropriate for other PROs such as patient satisfac-
tion or well being or the impact of the condition on qual-
ity of life which depend on much more than the clinical
outcomes achieved. These latter PROs will depend on the
demands of treatment and the extent to which the treat-
ment can be adapted to suit the individual without dam-
age to quality of life. It is crucial that we should be able to
measure these PROs without being required to show that
they map onto non-PROs! Indeed, it is perfectly possible
that despite bringing about improvements in clinical out-
comes a new treatment causes greater negative impact on
treatment satisfaction and quality of life and, if so,
patients are unlikely to be able to maintain clinical
improvements in the long term.
Linguistic validation (LV) of PRO measures
Some pharmaceutical companies who have previously
paid only lip service to the need for linguistic validation,
are now accepting that this is a task for specialists who will
take 5 months to conduct a full linguistic validation of a
questionnaire into another language. I have long collabo-
rated with Mapi in Lyon on LV work. There are cheaper
competitors who will complete the work in a fraction of
the time, but experience has shown me that this is a false
economy as high standards cannot be met at such speed.Page 5 of 8
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ance on the quality of LV work required to produce good
translations of PRO measures. In particular it would be
helpful to note that it is good practice for the developer of
the measure to be closely involved in the LV work. I
employ a full-time linguist to manage my collection of
translations and she and I are actively involved in LVs of
my questionnaires. Even so, I still recommend that con-
firmatory factor analysis be used to check the psychomet-
ric properties of the new translations when first used.
Blinding and randomisation
I must take issue with the statement that 'open-label studies,
where patients and investigators are aware of assigned therapy,
are rarely credible' (line 717–8). In chronic disorders such
as diabetes, all participants in trials will receive active
treatment and the issue is more often whether they receive
a new treatment or continue with an existing treatment
rather than whether they receive active treatment or pla-
cebo. New treatments may carry risks and possible
unwanted effects as well as benefits and it is not appropri-
ate to assume that patients will always be more positive
about a new treatment than about an old treatment. It is
said on line 721 that 'Every effort should be made to assure
that patients are masked to treatment assignment throughout
the trial'. In practice this may mean that patients are asked
to use two treatments, one of which is a placebo. This
places additional demands on the patients that do not
reflect the clinical realities of either treatment and render
the trial unsuitable for evaluating the impact of treatments
on patient satisfaction or quality of life. While I agree that
'The impact of unblinding is important to consider in the inter-
pretation of study results' (line 723) it is equally important
to consider the impact of blinding on study results. Blind-
ing should not be assumed to be universally desirable and
in itself can distort study results.
John Powers from the FDA in his introductory talk in
Washington referred to a paper by Iain Chalmers and col-
leagues [41] which compared trials that were more rigor-
ously blinded with those that were less so and showed
that the less rigorously blinded or open trials reported big-
ger effect sizes. The assumption made by Iain Chalmers
and colleagues and by John Powers seemed to be that
unblinded trials overestimate treatment effects compared
with blinded trials but no support was offered for this
assumption. It is equally possible that artificially blinded
trials, that abandon external validity in their efforts for
control, underestimate treatment effects compared with
more naturalistic unblinded trials which provide more
valid estimates of treatment effects.
Line 726 suggested that 'questions that ask how patients' cur-
rent status compares to baseline seem likely to be more influ-
enced by unblinding (optimism can readily be expressed as a
favourable comparison) than questions about current status
(which requires a current assessment, not a statement about
duration)' (I think the FDA probably mean 'differences'
rather than 'duration' here.) It is particularly frustrating
that there is no reference given for evidence for this point.
In my experience of using the DTSQs (status measure) and
the DTSQc (change measure) we often see that the DTSQc
shows greater improvements in satisfaction with treat-
ment than are shown by the DTSQs. However, separate
analysis of patients who scored at or near ceiling on the
DTSQs at baseline and patients who had more room to
show improvement in satisfaction showed clearly that
ceiling effects were limiting the benefits shown when the
status measure alone was used and the DTSQc provided a
more accurate representation of the benefits patients
experienced [5]. It is possible that other studies showing
fewer benefits with status measures than with change
measures are in fact underestimating the benefits of treat-
ment due to ceiling effects with the status measures that
are overcome by using change measures.
Statistical considerations for patient-level missing data
Line 1004 refers to imperfect strategies that 'try to predict
missing outcomes for a patient who has withdrawn from the
trial using data from subjects* who stayed in the trial and for
whom all data have been collected'. Participants who with-
draw from trials are likely to have worse scores on PROs
such as treatment satisfaction measures than are those
who continue in a trial and to impute missing values for
those who withdraw from those who remain is likely to
overestimate patient satisfaction. It would be much more
informative to give the PRO measure to participants who
withdraw early or to include interim data collections of
PROs for use in endpoint analyses.
* Subjects
The British Psychological Society advises that the term
'subjects' not be used as it can cause offence and suggests to
some potential participants that they may be subjected to
unpleasant experiences. The FDA might wish to refer to
'participants', 'respondents' or 'individuals' instead.
Copyright
No mention is given of the need to respect copyright in
questionnaires. There has recently been an increased
demand for linguistic validation certificates documenting
the procedures used in the linguistic validation work to
produce new language versions of questionnaires and I
believe this has been driven by the demands of regulatory
bodies. It certainly seems to be a useful way of discourag-
ing unauthorised translations and ensuring that only
authorised translations are sought and used. The FDA is in
an excellent position to encourage good practice in
obtaining PROs from copyright holders and discouraging
unlicensed use.Page 6 of 8
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PRO is a useful, broad term and it is not helpful to limit
the definition either by suggesting all PROs are measures
of health status (as the FDA did in the draft guidance) or
by defining PROs as 'feelings or function' affected by disease
(as they did at the Washington meeting). It is essential
that quality of life and health status are seen as two differ-
ent kinds of PRO and that neither be used to subsume the
other. If health status is used as an umbrella term it will
wrongly suggest that QoL is determined exclusively by
health and will do nothing to discourage the all-too-wide-
spread practice of measuring quality of health and misin-
terpreting the findings as if they were measuring QoL. The
FDA added confusion rather than clarity with their glos-
sary definition of QoL in terms of well-being which
remained undefined. If we define QoL as 'What the indi-
vidual thinks it is [32] and measure it using individualised
measures (e.g. [19,33]) it is a useful concept and arguably
the most important outcome measure of all. The FDA's
definition of the term HRQOL obscured the essential dif-
ference between health status measures and QoL meas-
ures by omitting to specify that the perceived impact to be
measured should be the impact of the condition and its
treatment on QoL (HRQoL) rather than simply the
impact of the condition and its treatment on health
(health status). It may be necessary to abandon the much
abused term HRQoL for a while in favour of 'condition-
dependent QoL' or 'condition-specific QoL' to break the wide-
spread habit of wrongly referring to health status tools as
HRQoL measures.
Key aspects of the draft guidelines discussed here included
the following:
• I have taken issue with the FDA's suggestion that
improvement needs to be demonstrated in all of the
important domains of a 'HRQoL' instrument. I can see no
basis for such an all-or-nothing approach for either health
status or QoL instruments, and no precedent in require-
ments for clinical measures.
• The FDA warned against instruments that ask patients to
make direct comparison of their current state with a previ-
ous state. I have argued that change measures are valuable
in overcoming ceiling effects common in status measures
of treatment satisfaction and can provide more, not less,
accurate estimates of change experienced [5,6].
• I disagree with the FDA's view that asymmetric response
options necessarily bias responding and give evidence for
the value of such asymmetry. I also provide evidence for
the value of weighting in conveying individuals' views of
the impact of their condition on QoL.
• Efforts to measure minimally important differences
recounted by the FDA were not impressive and I empha-
sise that it is crucial that we should be able to measure
PROs without being expected to show that they map onto
biomedical measures.
• I welcome the discussion of the importance of linguistic
validation (LV) of PRO measures for use in multi-national
trials though suggest that there needs to be more guidance
on the quality of LV work which ideally should involve
the developer and include patient testing if optimal qual-
ity is to be achieved. The requirement of some regulatory
bodies for LV certificates from the copyright owner which
document the LV work conducted to produce each trans-
lation is particularly useful in raising awareness of the LV
work needed and in preventing unauthorised translation
and use of questionnaires – a problem that the FDA might
helpfully discourage.
• Dismissing open-label trials as 'rarely credible', the FDA
revealed an uncritical view of 'blinding' as a universal ben-
efit when blinding can cause more problems than it solves
when PROs are a focus of trials. In evaluating the impact
of treatment on treatment satisfaction and other PROs it
is essential that the treatment reflects clinical realities
without the addition of placebo treatments in attempts to
mask treatment assignment.
• Missing data are also problematic for interpreting PROs
but substituting data from those who complete the trial
will mislead as their outcomes are likely to be more posi-
tive than those who discontinue. Better to give PRO meas-
ures to participants who withdraw early or bring forward
interim data for use in endpoint analyses.
• Finally, it is essential that the FDA provide references to
support the advice they give in their guidance if it is to be
useful in improving the standards applied in developing
and using PROs.
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